London · Delayed Price · Currency is GBP · Price in SEK Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of GBP 85.64 million. The enterprise value is 90.95 million.
| Market Cap | 85.64M |
| Enterprise Value | 90.95M |
Important Dates
The last earnings date was Thursday, August 21, 2025.
| Earnings Date | Aug 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 211.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.40% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 182.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.93 |
| PB Ratio | -16.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.43 |
| EV / Sales | 22.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.64 |
Financial Position
The company has a current ratio of 1.72
| Current Ratio | 1.72 |
| Quick Ratio | 1.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.42 |
| Interest Coverage | -14.47 |
Financial Efficiency
Return on equity (ROE) is -423.80% and return on invested capital (ROIC) is -85.90%.
| Return on Equity (ROE) | -423.80% |
| Return on Assets (ROA) | -55.09% |
| Return on Invested Capital (ROIC) | -85.90% |
| Return on Capital Employed (ROCE) | -370.33% |
| Revenue Per Employee | 52,061 |
| Profits Per Employee | -273,433 |
| Employee Count | 80 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.29 |
Taxes
In the past 12 months, Oncopeptides AB has paid 39,683 in taxes.
| Income Tax | 39,683 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +138.93% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +138.93% |
| 50-Day Moving Average | 4.72 |
| 200-Day Moving Average | 2.40 |
| Relative Strength Index (RSI) | 50.30 |
| Average Volume (20 Days) | 21,787 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of GBP 3.90 million and -20.51 million in losses. Loss per share was -0.10.
| Revenue | 3.90M |
| Gross Profit | 3.77M |
| Operating Income | -19.94M |
| Pretax Income | -20.47M |
| Net Income | -20.51M |
| EBITDA | -19.75M |
| EBIT | -19.94M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 5.38 million in cash and 10.52 million in debt, giving a net cash position of -5.13 million.
| Cash & Cash Equivalents | 5.38M |
| Total Debt | 10.52M |
| Net Cash | -5.13M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -5.13M |
| Book Value Per Share | -0.02 |
| Working Capital | 3.67M |
Cash Flow
In the last 12 months, operating cash flow was -24.92 million and capital expenditures -27,402, giving a free cash flow of -24.95 million.
| Operating Cash Flow | -24.92M |
| Capital Expenditures | -27,402 |
| Free Cash Flow | -24.95M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 96.58% |
| Operating Margin | -510.60% |
| Pretax Margin | -524.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.40% |
| Shareholder Yield | n/a |
| Earnings Yield | -23.95% |
| FCF Yield | -29.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |